METHODS FOR PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) USING SEROLOGIC MARKERS
The present invention provides methods, systems, and code for accurately classifying whether a sample from a pediatric individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from a pediatric individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.
1 . A method for classifying whether a sample from a pediatric subject is associated with inflammatory bowel disease (IBD), said method comprising:
(a) obtaining said sample from a pediatric individual;
(b) transforming said sample to determine the presence or level of one or more markers, which markers include an anti-flagellin antibody; and
(c) classifying said sample as an IBD sample or non-IBD sample using a statistical algorithm based upon the presence or level of one or more markers which includes said anti-flagellin antibody.
2 . The method of claim 1 , wherein said anti-flagellin antibody is an anti-CBir-1 antibody.
3 . The method of claim 2 , wherein the level of said anti-CBir-1 antibody is elevated in an IBD sample compared to a non-IBD sample.
4 . The method of claim 3 , wherein said IBD sample is a Crohn's Disease sample.
5 . The method of claim 1 , wherein one or more markers is selected from the group consisting of ANCA, pANCA, ASCA-IgA, ASCA-IgG, anti-OmpC antibodies, and a combination thereof.
6 . The method of claim 1 , wherein one or more markers is ASCA-IgA.
7 . The method of claim 6 , wherein the level of ASCA-IgA in an IBD sample compared to a non-IBD sample is normal.
8 . The method of claim 1 , wherein one or more markers is ASCA-IgG.
9 . The method of claim 8 , wherein the level of ASCA-IgG in an IBD sample compared to a non-IBD sample is normal.
10 . The method of claim 1 , wherein one or more markers is only said anti-flagellin antibody.
11 . A method for diagnosing whether a sample from a pediatric individual is associated with inflammatory bowel disease (IBD), said method comprising:
(a) obtaining said sample from said pediatric individual;
(b) transforming said sample to determine the presence or level of one or more markers, which markers include an anti-flagellin antibody marker; and
(c) classifying said sample as an IBD sample or non-IBD sample using a statistical algorithm based upon the presence or level of one or more markers which includes said anti-flagellin antibody.
12 . The method of claim 11 , wherein said anti-flagellin antibody is an anti-CBir-1 antibody.
13 . The method of claim 12 , wherein the level of said anti-CBir-1 antibody is elevated in an IBD sample compared to a non-IBD sample.
14 . The method of claim 13 , wherein said IBD sample is a Crohn's Disease sample.
15 . The method of claim 11 , wherein one or more markers is selected from the group consisting of ANCA, pANCA, ASCA-IgA, ASCA-IgG, anti-OmpC antibodies, and a combination thereof.
16 . The method of claim 11 , wherein one or more markers is ASCA-IgA.
17 . The method of claim 16 , wherein the level of ASCA-IgA in an IBD sample compared to a non-IBD sample is normal.
18 . The method of claim 11 , wherein one or more markers is ASCA-IgG.
19 . The method of claim 18 , wherein the level of ASCA-IgG in an IBD sample compared to a non-IBD sample is normal.
20 . The method of claim 11 , wherein one or more markers is only said anti-flagellin antibody.